Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

NCT03588091 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

355

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: Placebo Oral Tablet
DRUG: Trastuzumab
DRUG: Docetaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.